Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil

Evaluation of in vitro activity of ceftolozane–tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study

(2020) Felipe Francisco Tuon et al.   Brazilian Journal of Infectious Diseases

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China

(2020) Xiaoyan Cui et al.   Frontiers in Microbiology

Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model

(2019) Joan Gómez-Junyent et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients

(2019) Giovanni Gherardi et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Comparative Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from United States Hospitals

(2019) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

NDM and other mechanisms of carbapenemases among Enterobacteriaceae in rural South India

(2019) Ramalingam Sekar et al.   Journal of Global Antimicrobial Resistance

Resistance to Ceftazidime-Avibactam and Underlying Mechanisms

(2019) Yuhang Wang et al.   Journal of Global Antimicrobial Resistance

Prevalence and molecular features of ESBL/pAmpC-producing Enterobacteriaceae in healthy and diseased companion animals in Brazil

(2018) Luana C. Melo et al.   VETERINARY MICROBIOLOGY

Rapid rise of the ESBL and mcr-1 genes in Escherichia coli of chicken origin in China, 2008–2014

(2018) Congming Wu et al.   Emerging Microbes & Infections

Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers

(2018) Cecilia G. Carvalhaes et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review

(2017) Felipe Francisco Tuon et al.   INFECTION

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa

(2017) Adnan Alatoom et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms

(2017) Domenico Schillaci et al.   JOURNAL OF MEDICINAL CHEMISTRY

In VitroSusceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)

(2016) Boudewijn L. M. de Jonge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The negative impact of antibiotic resistance

(2016) N.D. Friedman et al.   CLINICAL MICROBIOLOGY AND INFECTION

The role of the genetic elements bla oxa and IS Aba 1 in the Acinetobacter calcoaceticus-Acinetobacter baumannii complex in carbapenem resistance in the hospital setting

(2016) Vanessa Cristine Kobs et al.   Revista da Sociedade Brasileira de Medicina Tropical

The global epidemiology of carbapenemase-producing Enterobacteriaceae

(2016) David van Duin et al.   Virulence

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION